SpyGlass Pharma, Inc. (SGP)
Nasdaq · Healthcare · Biotechnology
$25.59+2.69%as of Oct 6, 2026, 1:35 AM ET
- Market cap
- $856M
- 52-week range
- $17.06 – $32.44
- 52-week change
- −5.61%
- EPS (trailing)
- −$2.51
- Analyst rating
- 1.2 Strong buy
- Next earnings
- Nov 5, 2026
Fiscal year to Dec 2025
- Net income
- −$39.9M
- Diluted EPS
- −$17.98
- Free cash flow
- −$33.5M
From the company’s annual report on SEC EDGAR.
About SpyGlass Pharma, Inc.
SpyGlass Pharma, Inc. operates as a biopharmaceutical company that provides treatment and drug delivery for patients living with chronic eye conditions. The company develops the Bimatoprost Drug Pad-IOL System (BIM-IOL System), including novel and proprietary drug pads attached to an intraocular lens (IOL), which is designed to be implanted during routine cataract surgery to reduce elevated intraocular pressure (IOP) in patients. It also develops a non-IOL-based, ring-shaped, sustained-release implant with bimatoprost. SpyGlass Pharma, Inc. was formerly known as SpyGlass Ophthalmics, Inc. and changed its name to SpyGlass Pharma, Inc. in April 2021. The company was headquartered in 2019 and is based in Irvine, California.
Headquarters: Irvine, United States · 76 employees · spyglasspharma.com